SkinBioTherapeutics Plc (LSE:SBTX) spent more than two months of 2026 suspended from the London Stock Exchange's junior market while forensic accountants worked through accounts that turned out to include Revenue supported by fabricated paperwork. The Newcastle-based health and beauty group is now back on AIM, with an interim chair, an interim chief executive, restated numbers and a promise of fresh market guidance later this year.
The underlying business, which sells foot-care products through Boots, Superdrug and the NHS, AxisBiotix gut-skin supplements and contract Manufacturing services, grew revenue by 37% in the first half of its financial year. The question is whether that operational story can now be separated from the governance failure that nearly derailed it.
Half-year results, a restatement and a return to trading on 8 June 2026
The pivotal announcement came on 8 June 2026, when SkinBioTherapeutics published delayed half-year results for the six months to 31 December 2025 alongside restated, unaudited results for the year to 30 June 2025. Trading in the shares, suspended on 1 April 2026 because the interims had missed the AIM Rules deadline of 31 March, was restored the same day.
On 13 February 2026 the company had announced that chief executive Stuart Ashman resigned after being suspended by the board pending an inquiry into his conduct, with FRP Advisory appointed to carry out an independent forensic review.
The findings were stark. Accrued Royalty revenue of £0.77m recognised in FY25 was found to be inappropriate, and the company said FRP concluded the former chief executive had fabricated the supporting documentation, with no evidence others were involved. Director Bonus payments of £0.23m were also incorrectly timed across FY24 and FY25; Martin Hunt and Dr Cathy Prescott voluntarily repaid the disputed amounts. No issues were identified with reported cash balances. Investigation costs to date were put at roughly £0.7m, which the company is seeking to recover.
Interim chair Alyson Levett said the board could "now confirm that all material issues have been identified". Interim chief executive Rachel Parsonage said "a line can now be drawn under what has happened". Hunt and Prescott left the board on 8 June. On 25 June the company said chief financial officer Emily Bertram, credited with helping to identify the issues, would leave on 30 June, with an interim CFO engaged on a non-board basis.
What SkinBioTherapeutics actually sells
The company describes itself as having evolved from a research-based Business into a commercial health and beauty group. Within products, Dermatonics supplies clinically validated foot-care ranges to the NHS, specialist podiatrists and chains including Boots and Superdrug, and a Brand refresh focused on podiatry is under way. AxisBiotix is the gut-skin axis supplement line: Skin Calm is sold through the company's website, Amazon and around 180 Superdrug stores under a two-year exclusivity deal, and Skin Clear launched in March 2026. The third strand is intellectual property: the SkinBiotix and Zenakine technology is licensed to Croda, the FTSE-listed speciality chemicals group, with royalties now recognised only when confirmed sales data is received.
The services division is Bio-Tech Solutions, a contract manufacturing and packaging business serving the NHS, medical wholesalers and veterinary distributors.
The numbers: revenue up 37%, losses steady, cash tighter
For the six months to 31 December 2025, revenue rose 37.4% to £2.17m from £1.58m a year earlier. Gross Margin held at 55.6% (HY25: 55.7%). The operating loss narrowed slightly to £1.00m from £1.03m, the loss before tax was £0.79m and the loss per share was 0.31p against 0.46p. Cash at 31 December 2025 was £3.1m, up from £1.2m a year earlier, reflecting Equity raised in 2025.
Growth came almost entirely from Bio-Tech Solutions, which contributed £1.2m against £0.4m. Dermatonics was flat at £0.98m (HY25: £1.0m), while AxisBiotix Skin Calm sales rose to £172k from £133k.
The restated FY25 figures show how much the investigation changed the picture. Revenue for the year to 30 June 2025 was cut to £3.87m from the £4.64m originally reported in December 2025, and the operating loss widened to £2.13m from £1.12m. The loss before tax was £1.72m and the loss per share 0.77p. Cash at 30 June 2025 of £4.78m was unaffected.
Net cash used in Operating Activities in HY26 was £1.51m, and cash stood at £1.5m on 31 May 2026 after investigation costs. The directors nonetheless adopted the going-concern basis, stating the group has adequate resources for the foreseeable future. No Dividend is paid.
What could move the shares next
The most concrete near-term catalyst is the market guidance the board has committed to issuing later in 2026, together with an investor presentation on FY26 strategy. Full-year results for the year to 30 June 2026 will be the first prepared entirely under new leadership, and will show whether the FY25 restatement ended the accounting clean-up.
Operationally, the Croda licence is the largest potential source of high-margin revenue, though royalties are now booked only on confirmed sales. AxisBiotix at Superdrug, the Dermatonics refresh and efficiency work at Bio-Tech Solutions are the other levers management has flagged. Recovery of any of the £0.7m investigation cost would help a thin cash position.
On 27 July 2026 the company disclosed that Mark and Diana Dixon had lifted their holding, via Rock Nominees, to 29.324% from 28.359%. Appointment of new non-executive directors and a permanent CEO and CFO would signal that governance rebuilding is complete.
Risks investors should watch
The governance failure is the defining risk. A chief executive fabricated documents that inflated reported revenue, and the board itself acknowledged corporate governance weaknesses. Remediation is under way, but the company currently has an interim chair, an interim CEO and a non-board interim CFO.
Funding is the second concern. With £1.5m of cash at the end of May 2026 and an operating cash outflow of £1.51m in the preceding six months, headroom is limited unless losses narrow quickly. A dilutive equity raise cannot be ruled out; the company last tapped shareholders through a retail offer in June 2025.
Revenue quality is a third issue. HY26 growth was driven by contract manufacturing rather than the higher-margin consumer and IP lines, Dermatonics was flat, and the restated FY25 figures remain unaudited. Finally, the register is concentrated, with one family interest just below the 30% mandatory-offer threshold.
Outlook
SkinBioTherapeutics (LSE:SBTX) enters the autumn of 2026 having survived a serious integrity failure with its cash balances intact and its commercial partnerships, including the Croda licence, apparently in place. Revenue is growing, gross margins are stable and the interim board has been candid about what went wrong.
The next milestones are the promised guidance and strategy presentation, the FY26 results, a permanent Leadership team and evidence that cash burn is falling. Investors will need to judge whether new management can turn a credible product portfolio into a self-funding business before the Balance Sheet forces the question.






Please wait processing your request...